|
Re: Shrinking MACE event rate
|
4
|
Resverlogix Corp.
|
Jan 21, 2019 10:44AM
|
|
Re: BRD2 involvement in Covid19
|
4
|
Resverlogix Corp.
|
Mar 18, 2020 07:41PM
|
|
Re: Apabetalone inhibits kidney damage in diabetes
|
4
|
Resverlogix Corp.
|
Aug 23, 2024 08:45AM
|
|
Re: A healthy debate....
|
4
|
Resverlogix Corp.
|
Jun 03, 2019 01:21PM
|
|
Re: What's the deal with Zenith?
|
4
|
Zenith Epigenetics
|
Jun 23, 2023 09:47AM
|
|
Re: Potential Suitor
|
4
|
Resverlogix Corp.
|
Sep 13, 2020 08:03AM
|
|
Re: Debt
|
4
|
Zenith Epigenetics
|
Apr 03, 2022 04:08PM
|
|
Re: New insights from this study -- Questions for scientists.
|
4
|
Resverlogix Corp.
|
Jun 09, 2022 01:49PM
|
|
Re: SF
|
4
|
Resverlogix Corp.
|
Sep 17, 2020 02:02PM
|
|
Re: Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
|
4
|
Resverlogix Corp.
|
Oct 26, 2023 12:54PM
|
|
Re: Why I think it's a homerun
|
4
|
Resverlogix Corp.
|
Mar 03, 2019 05:24PM
|
|
Re: Additional Exempt Distribution- 2023-03-31
|
4
|
Zenith Epigenetics
|
Apr 12, 2023 10:54AM
|
|
Re: New paper
|
4
|
Resverlogix Corp.
|
Mar 19, 2023 04:03PM
|
|
AND, APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE
|
4
|
Resverlogix Corp.
|
Jun 05, 2020 06:07PM
|
|
Re: ZCC relationship to ZEL!
|
4
|
Zenith Epigenetics
|
Apr 02, 2019 03:38PM
|
|
Re: find it interesting that RVXCF.....
|
4
|
Resverlogix Corp.
|
Nov 10, 2022 01:35PM
|
|
Re: Timelines
|
4
|
Resverlogix Corp.
|
Aug 27, 2019 09:18AM
|
|
Re: Up Up Up- Level II
|
4
|
Resverlogix Corp.
|
Sep 17, 2020 02:37PM
|
|
Re: Market Woes
|
4
|
Resverlogix Corp.
|
May 01, 2022 07:57PM
|
|
New-Report of exempt distribution
|
4
|
Resverlogix Corp.
|
Jan 05, 2021 04:22PM
|
